Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iGlarLixi vs Gla-100 on Glycemic Time in Range in Chinese Insulin Naïve T2D Patients
NCT06671587Phase 4Recruiting
- Sponsor
- Sanofi
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin glargine + lixisenatide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Mean change in the percentage of Time in Range [3.9-10.0 mmol/L (70-180 mg/dL)] at 20 weeks. Started Dec 2024; status: recruiting.
02
Drugs
insulin glargine + lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06671587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671587.